報價延遲最少15分鐘:2025/01/21 05:36 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.07 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.59/--
|
|
企業價值
64.98M
|
| 資產負債 |
|
每股賬面淨值
-1.94
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
12.06M
|
|
每股收益
0.47
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/21 05:36 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Accelerate Diagnostics Inc is an in vitro diagnostics company that specializes in rapid diagnostics for infectious pathogens. The firm's core platform, the Accelerate ID/AST System, determines whether live bacterial or fungal cells in a patient sample are susceptible to a particular antibiotic. This test is performed on pathogens that are commonly associated with serious infections and can deliver results more quickly than traditional methods, such as bacterial culturing. The system can analyze a positive blood culture sample in approximately five hours, which is faster than traditional testing techniques. The company earns majority of its revenue from domestic market. |